Rocco Michael V, Rigaud Marion, Ertel Carole, Russell Greg, Zemdegs Juliane, Vecchio Mariacristina
Wake Forest University School of Medicine, Section on Nephrology, Winston-Salem, NC.
Danone Research, Palaiseau, France.
Kidney Med. 2023 Jul 26;5(9):100703. doi: 10.1016/j.xkme.2023.100703. eCollection 2023 Sep.
RATIONALE & OBJECTIVE: Increased interdialytic weight gain (IDWG) has been associated with increased morbidity and mortality. We evaluated the usefulness and safety of a mobile application (app) that allows patients receiving maintenance hemodialysis to self-monitor their daily fluid intake.
Within group comparison before or during intervention.
SETTING & PARTICIPANTS: Patients receiving maintenance hemodialysis with mean IDWG of <4%.
Participants were trained to use a smartphone-based app, FiApp that allowed them to record fluid intake and compare with individual targeted daily fluid intake determined by the nephrologist.
The primary study outcome was the association between IDWG and fluid intake recorded in the FiApp. Secondary outcomes included FiApp safety and usage. Patient interviews were performed at weeks 1 and 4 to collect information regarding FiApp usability and recommendations for app improvements.
Mean, median, and standard deviation.
Eighteen of 25 patients completed the full 4-week study, provided all app data, and completed 2 patient interviews. The mean 4-week IDWG during app use was similar to the baseline mean 4-week IDWG before app use; however, 61% of the participants had a decrease in IDWG when using the app compared with IDWG at baseline. Of the 18 participants who completed the study, only 1 had a mean 4-week IDWG that was 20% higher than that at baseline. The app was used on ≥80% of the days by 13 (72%) of 18 participants, and was used every day in 7 (39%) of 18 participants. The mean relationship between fluid reported in the app and fluid consumed was 40%.
This safety study recruited patients who had IDWG of <4%.
A smartphone-based app can be safely used to help patients receiving maintenance hemodialysis track and control fluid intake. Motivated patients were able to decrease IDWG despite baseline IDWG being <4% of the body weight.
NCT03759847.
PLAIN-LANGUAGE SUMMARY: Patients receiving maintenance hemodialysis struggle to limit fluid intake. Excess fluid intake can lead to adverse cardiovascular events. We developed a smartphone app to help patients receiving dialysis self-monitor their fluid intake. In this safety study in patients receiving dialysis with an interdialytic weight gain of <4% of the body weight, more than half of the patients were able to decrease their interdialytic fluid intake while using the app, and only 1 patient had an increase in interdialytic weight gain of >20% while using the app. Information gleaned from structured patient interviews will be used to refine this app.
透析间期体重增加(IDWG)增加与发病率和死亡率升高相关。我们评估了一款移动应用程序(应用)的有效性和安全性,该应用可让接受维持性血液透析的患者自我监测每日液体摄入量。
干预前或干预期间的组内比较。
接受维持性血液透析且平均IDWG<4%的患者。
参与者接受培训以使用一款基于智能手机的应用程序FiApp,该应用程序可让他们记录液体摄入量,并与肾病医生确定的个体每日目标液体摄入量进行比较。
主要研究结果是IDWG与FiApp中记录的液体摄入量之间的关联。次要结果包括FiApp的安全性和使用情况。在第1周和第4周进行患者访谈,以收集有关FiApp可用性的信息以及对应用改进的建议。
均值、中位数和标准差。
25名患者中有18名完成了为期4周的完整研究,提供了所有应用程序数据,并完成了2次患者访谈。应用程序使用期间的平均4周IDWG与应用程序使用前的基线平均4周IDWG相似;然而,与基线时的IDWG相比,61%的参与者在使用应用程序时IDWG有所下降。在完成研究的18名参与者中,只有1人的平均4周IDWG比基线时高20%。18名参与者中有13名(72%)在≥80%的天数使用了该应用程序,18名参与者中有7名(39%)每天都使用该应用程序。应用程序中报告的液体与消耗的液体之间的平均关系为40%。
这项安全性研究招募的患者IDWG<4%。
一款基于智能手机的应用程序可安全用于帮助接受维持性血液透析的患者追踪和控制液体摄入量。尽管基线IDWG<体重的4%,但有积极性的患者能够降低IDWG。
NCT03759847。
接受维持性血液透析的患者难以限制液体摄入量。过量的液体摄入会导致不良心血管事件。我们开发了一款智能手机应用程序来帮助接受透析的患者自我监测液体摄入量。在这项针对透析间期体重增加<体重4%的透析患者的安全性研究中,超过一半的患者在使用该应用程序时能够减少透析间期液体摄入量,并且只有1名患者在使用该应用程序时透析间期体重增加超过20%。从结构化患者访谈中收集到的信息将用于完善此应用程序。